If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Retevmo ® (selpercatinib) capsules
40 mg, 80 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How is Retevmo® (selpercatinib) metabolized?
Selpercatinib is metabolized mostly by CYP3A4.
Metabolism of Selpercatinib
Selpercatinib is metabolized predominantly by cytochrome P450 (CYP3A4). Following oral administration of a single [14C] radiolabeled 160 mg dose of selpercatinib to healthy subjects, unchanged selpercatinib constituted 86% of the measured radioactive drug components in plasma.1
Enclosed Prescribing Information
Reference
1Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: January 04, 2023